Clinical Scenario: Persistent CIS and High-Grade Ta Bladder Cancer After BCGRecurrent carcinoma in situElderlyBCG failureAlternative treatmentsThe standard treatment for Ta-T1 high-grade (G3) TCC of the bladder and CIS is TUR followed by BCG full dose once a week for 6 weeks and then at ...
Following surgery, intravesical maintenance therapy with BCG may be recommended. If patients do not tolerate or respond well to BCG, they can receive intravesical chemotherapy with mitomycin and gemcitabine. In response to ongoing BCG shortages, vials of BCG can be divided into thirds; however, the...
One treatment, bacillus Calmette-Guerin (BCG) therapy, sends in helpful bacteria through a catheter directly to your bladder that trigger the immune system. BCG is used for cancers that haven't spread. Another type of therapy, immune checkpoint inhibitors, targets certain proteins on cancer cells...
Subsequent treatment is as follows: Small-volume, low-grade Ta bladder cancer - An immediate single, postoperative dose of intravesical chemotherapy Intermediate-risk bladder cancer (recurrent low grade, high volume low grade, high-grade Ta) – Intravesical chemotherapy or BCG High-risk Ta, T1,...
8 After surgical treatment of bladder cancer, primary care physicians should monitor a patient’s overall tolerance of this procedure. Patients may need assistance with continence, sexual health, and body image. Table 3. Surveillance of muscle-invasive disease LaboratoryRadiologyCytology/Cystoscopy Renal...
The bladder tumour microbiome and BCG response Louise Lloyd Research Highlights18 Jun 2024Nature Reviews Urology Volume: 21, P: 389 Bladder cancer variants — one disease with many faces Bladder cancer progression to microscopically distinct variants such as sarcomatoid, small cell, micropapillary and ...
Immunosensitivity of the bladder cancer as established byBCGtherapy 4. Unmet medical need for therapy targetingsuperficial bladder cancerafter relapse 5. Decreased relevance of immune clearance, e.g.neutralizing antibodies, due to local application of the agent within the confines of the bladder. ...
5Claps F, et al. BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.Int J Mol Sci.2023;24(16):12596. 6Brooks NA, O’Donnell MA. Treatment options in non-muscle-invasive ...
0:51 |More recently, we have seen the introduction of immune checkpoint inhibitors in the non-muscle invasive BCG-unresponsive setting. In a different clinical indication, we've seen the introduction of immune checkpoint inhibitors in the high-risk adjuvant or post-operative setting as well. ...
administer is cost. Bladder cancer is the [costliest] cancer of all cancer types. We need to be more judicious on how we allocate treatment but also to the availability. This is a chemotherapeutic agent and does not need to be grown, such as what we see with BCG. That is not a ...